These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 12160194)

  • 21. Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction.
    Udelson JE; Feldman AM; Greenberg B; Pitt B; Mukherjee R; Solomon HA; Konstam MA
    Circ Heart Fail; 2010 May; 3(3):347-53. PubMed ID: 20299607
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low-dose eplerenone decreases left ventricular mass in treatment-resistant hypertension.
    Schneider A; Schwab J; Karg MV; Kalizki T; Reinold A; Schneider MP; Schmieder RE; Schmidt BM
    J Hypertens; 2017 May; 35(5):1086-1092. PubMed ID: 28118280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension.
    Hollenberg NK; Williams GH; Anderson R; Akhras KS; Bittman RM; Krause SL
    Arch Intern Med; 2003 Jul; 163(13):1543-8. PubMed ID: 12860576
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A twelve-week, multicenter, randomized, double-blind, parallel-group, noninferiority trial of the antihypertensive efficacy and tolerability of imidapril and candesartan in adult patients with mild to moderate essential hypertension: the Iberian Multicenter Imidapril Study on Hypertension (IMISH).
    Palma Gámiz JL; Pêgo M; Contreras EM; Anglada MP; Martínez JO; Esquerra EA; Sagastagoitia Gorostiza JD;
    Clin Ther; 2006 Dec; 28(12):2040-51. PubMed ID: 17296460
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring.
    Lacourcière Y; Neutel JM; Davidai G; Koval S
    Am J Hypertens; 2006 Jan; 19(1):104-12. PubMed ID: 16461201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The velocity of home blood pressure reduction in response to low-dose eplerenone combined with other antihypertensive drugs determined by exponential decay function analysis.
    Elnagar N; Satoh M; Hosaka M; Asayama K; Ishikura K; Obara T; Mano N; Ohkubo T; Imai Y
    Clin Exp Hypertens; 2014; 36(2):83-91. PubMed ID: 24625334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can renin status predict the antihypertensive efficacy of eplerenone add-on therapy?
    Prisant LM; Krum H; Roniker B; Krause SL; Fakouhi K; He W
    J Clin Pharmacol; 2003 Nov; 43(11):1203-10. PubMed ID: 14551174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients.
    Savoia C; Touyz RM; Amiri F; Schiffrin EL
    Hypertension; 2008 Feb; 51(2):432-9. PubMed ID: 18195160
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Determinants of blood pressure reduction by eplerenone in uncontrolled hypertension.
    Jansen PM; Frenkel WJ; van den Born BJ; de Bruijne EL; Deinum J; Kerstens MN; Arnoldus JH; Woittiez AJ; Wijbenga JA; Zietse R; Danser AH; van den Meiracker AH
    J Hypertens; 2013 Feb; 31(2):404-13. PubMed ID: 23249826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of once-daily oral fimasartan 20 to 240 mg/d in Korean Patients with hypertension: findings from Two Phase II, randomized, double-blind, placebo-controlled studies.
    Lee H; Yang HM; Lee HY; Kim JJ; Choi DJ; Seung KB; Jeon ES; Ha JW; Rim SJ; Park JB; Shin JH; Oh BH
    Clin Ther; 2012 Jun; 34(6):1273-89. PubMed ID: 22608107
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of fosinopril/hydrochlorothiazide combinations on ambulatory blood pressure profiles in hypertension. Fosinopril/Hydrochlorothiazide Investigators.
    Guthrie R; Reggi DR; Plesher MM; Saini RK; Battikha JP
    Am J Hypertens; 1996 Apr; 9(4 Pt 1):306-11. PubMed ID: 8722432
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vascular Effects of Eplerenone in Coronary Artery Disease With Preserved Ejection Fraction: A Double-Blind, Randomized, Placebo-Controlled Trial.
    Sudano I; Naegele M; Roas S; Périat D; Frank M; Kouroedov A; Noll G; Lüscher TF; Enseleit F; Ruschitzka F; Flammer AJ
    Clin Cardiol; 2016 May; 39(5):285-90. PubMed ID: 26991772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aldosterone antagonism: an emerging strategy for effective blood pressure lowering.
    Pratt-Ubunama MN; Nishizaka MK; Calhoun DA
    Curr Hypertens Rep; 2005 Jun; 7(3):186-92. PubMed ID: 15913492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mineralocorticoid Receptor Activation Contributes to the Supine Hypertension of Autonomic Failure.
    Arnold AC; Okamoto LE; Gamboa A; Black BK; Raj SR; Elijovich F; Robertson D; Shibao CA; Biaggioni I
    Hypertension; 2016 Feb; 67(2):424-9. PubMed ID: 26644241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized trial of the aldosterone-receptor antagonist eplerenone in asymptomatic moderate-severe aortic stenosis.
    Stewart RA; Kerr AJ; Cowan BR; Young AA; Occleshaw C; Richards AM; Edwards C; Whalley GA; Freidlander D; Williams M; Doughty RN; Zeng I; White HD;
    Am Heart J; 2008 Aug; 156(2):348-55. PubMed ID: 18657667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT).
    Václavík J; Sedlák R; Jarkovský J; Kociánová E; Táborský M
    Medicine (Baltimore); 2014 Dec; 93(27):e162. PubMed ID: 25501057
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ambulatory blood pressure response to once-daily fimasartan: an 8-week, multicenter, randomized, double-blind, active-comparator, parallel-group study in Korean patients with mild to moderate essential hypertension.
    Lee H; Kim KS; Chae SC; Jeong MH; Kim DS; Oh BH
    Clin Ther; 2013 Sep; 35(9):1337-49. PubMed ID: 23932463
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of eplerenone on blood pressure and the renin-angiotensin-aldosterone system in oligo-anuric chronic hemodialysis patients - a pilot study.
    Shavit L; Neykin D; Lifschitz M; Slotki I
    Clin Nephrol; 2011 Nov; 76(5):388-95. PubMed ID: 22000559
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.